Sonoma Biotherapeutics
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies aimed at treating autoimmune and inflammatory diseases by restoring immune system balance. The company employs proprietary cell-therapy platform technologies to engineer and deliver targeted Treg approaches designed for durable, disease-modifying treatment. Its services include preclinical development, clinical evaluation of Treg-based therapies, and collaboration frameworks for advancing new modalities in immune-mediated conditions. Sonoma Biotherapeutics engages with partners and stakeholders across research, manufacturing, and clinical operations to bring engineered cell therapies from concept toward clinical proof of concept.
Domain
sonomabio.com
Country
United StatesIndustry
BiotechnologyEmployees
101-250
Last Funding
$0.3M
Founded
2019
Tech Stack (26 technologies)
Frequently Asked Questions
What technologies does Sonoma Biotherapeutics use?+
Sonoma Biotherapeutics uses 26 technologies including Cookiebot, Google Analytics, jsDelivr.
What industry is Sonoma Biotherapeutics in?+
Sonoma Biotherapeutics operates in the Biotechnology industry.
Where is Sonoma Biotherapeutics based?+
Sonoma Biotherapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026